EGFR and triple-negative breast carcinoma: Among them, EGFR is overexpressed in more than 50% of triple-negative breast cancer (TNBC), which is characterized by lack of estrogen receptor, progesterone receptor, and HER2 expression, associated with poor clinical outcome and has limited treatment approaches7–9.